---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-025855"
form_type: "8-K"
ticker: "CRDF"
cik: "0001213037"
company_name: "Cardiff Oncology, Inc."
filed_at: "2022-10-03T23:59:59+00:00"
generated_at: "2026-06-23T05:51:22.028403+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Cardiff Oncology posts updated corporate presentation on onvansertib clinical pipeline

## Summary
- Presentation covers onvansertib as a PLK1 inhibitor with potential in KRAS-mutated cancers.
- Highlights ongoing Phase 1b/2 trials in mCRC, mPDAC, TNBC, and SCLC with historical ORR benchmarks.
- Includes strategic goals for 2022-2025: demonstration, confirmation, and positioning for registration.
- No specific new clinical data or financial guidance announced in the filing.

## SEC filing metadata
- accession: 0001628280-22-025855
- form_type: 8-K
- ticker: CRDF
- cik: 0001213037
- company_name: Cardiff Oncology, Inc.
- filed_at: 2022-10-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1213037/000162828022025855/0001628280-22-025855-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1213037/000162828022025855/crdf-20221003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-025855
- JSON: https://secwatch.observer/filing/0001628280-22-025855.json
- Plain text: https://secwatch.observer/filing/0001628280-22-025855.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.